×
SCD411 study/ Study Protocol SCD411-CP101

SCD411 study/ Study Protocol SCD411-CP101

This is a Phase III, one year study to compare the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity between SCD411 and Eylea in subjects with neovascular age-related macular degeneration. Participants are required to be treatment naïve.

Principal Investigator – Dr Fred Chen

For further information about this study please contact the Clinical Trials Office on (08) 9381 0750 or email clinicalresearch@lei.org.au

EUDRACT Number: 2019-004132-37

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

Request an appointment